All In Biotech

Drug Trial Radar · NCT06505941

Clinical Study on the Safety and Preliminary Efficacy of hUC-MSCs Intravenous Infusion Therapy for ARDS

Clinical Study on the Safety and Preliminary Efficacy of Umbilical Cord Mesenchymal Stem Cell Intravenous Infusion Therapy for Acute Respiratory Distress Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 20, 2024

Primary completion

Nov 20, 2025

Study completion Feb 20, 2027

Sponsor

Lead sponsor
Southeast University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zhongda Hospital; Yinguan Biologics, Shenzheng
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The object of this study is to observe the safety of umbilical cord mesenchymal stem cell therapy for acute respiratory distress syndrome, consisting with two phases.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

  • umbilical cord mesenchymal stem cellDrug

    umbilical cord mesenchymal stem cell

  • PlaceboDrug

    non-cell-containing placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of umbilical cord mesenchymal stem cell therapy for acute respiratory distress syndrome.Time frame: The 1, 6, 24 hours; 3、7、14、21 days and 4, 12, 24, 36, 48 weeks after injection.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.